Is PRURITUS a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PRURITUS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 78 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PRURITUS to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PRURITUS. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PRURITUS, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PRURITUS. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PRURITUS ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PRURITUS: 78
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PRURITUS is a reported side effect: 2.3430%

FDA reports of any drug causing PRURITUS : 63672
Average percentage for all medicated patients where PRURITUS is reported as a complication: 0.3991%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PRURITUS:

NIASPAN (8051 patients)
ASPIRIN (6506 patients)
HUMIRA (3548 patients)
SIMCOR (2495 patients)
LISINOPRIL (2206 patients)
ENBREL (2200 patients)
LIPITOR (2194 patients)
REMICADE (2043 patients)
MAGNEVIST (1936 patients)
SYNTHROID (1816 patients)
FOSAMAX (1670 patients)
PLAVIX (1666 patients)
PREDNISONE (1627 patients)
NEXIUM (1591 patients)
SIMVASTATIN (1579 patients)
OMEPRAZOLE (1556 patients)
LASIX (1484 patients)
CRESTOR (1401 patients)
ATENOLOL (1388 patients)
METHOTREXATE (1353 patients)
LEVOTHYROXINE SODIUM (1302 patients)
TYSABRI (1294 patients)
BENADRYL (1286 patients)
LYRICA (1284 patients)
VITAMIN D (1253 patients)
FOLIC ACID (1220 patients)
LAMICTAL (1201 patients)
FISH OIL (1191 patients)
HYDROCHLOROTHIAZIDE (1173 patients)
COUMADIN (1169 patients)
CHANTIX (1131 patients)
ACETAMINOPHEN (1125 patients)
NORVASC (1119 patients)
FUROSEMIDE (1100 patients)
CELEBREX (1038 patients)
XANAX (1013 patients)
PEGASYS (993 patients)
FORTEO (990 patients)
PRILOSEC (981 patients)
METFORMIN HCL (960 patients)
AVELOX (959 patients)
ALLOPURINOL (957 patients)
CYMBALTA (950 patients)
DIOVAN (949 patients)
HEPARIN SODIUM INJECTION (940 patients)
CALCIUM (937 patients)
RIBAVIRIN (935 patients)
IBUPROFEN (917 patients)
NEURONTIN (912 patients)
TOPROL-XL (889 patients)
SINGULAIR (873 patients)
METOPROLOL TARTRATE (869 patients)
NEXAVAR (851 patients)
ZYRTEC (838 patients)
ALBUTEROL (828 patients)
OMNISCAN (816 patients)
ADVAIR DISKUS 100/50 (795 patients)
AMLODIPINE (794 patients)
MULTI-VITAMIN (779 patients)
PROTONIX (765 patients)
ZOCOR (759 patients)
PREVACID (752 patients)
AMBIEN (743 patients)
SEROQUEL (738 patients)
ZOLOFT (725 patients)
VIOXX (714 patients)
LANTUS (710 patients)
AVONEX (710 patients)
REVLIMID (708 patients)
GABAPENTIN (695 patients)
LEXAPRO (674 patients)
PREDNISOLONE (669 patients)
XOLAIR (665 patients)
SPIRIVA (662 patients)
PREDNISONE TAB (661 patients)
LORAZEPAM (660 patients)
GLEEVEC (635 patients)
OXYCONTIN (633 patients)
PREMARIN (616 patients)
PAXIL (615 patients)
AUGMENTIN '125' (609 patients)
ZETIA (603 patients)
VICODIN (598 patients)
ALLEGRA (588 patients)
POTASSIUM CHLORIDE (584 patients)
ZOMETA (581 patients)
METOPROLOL (575 patients)
CLONAZEPAM (573 patients)
TRAMADOL HCL (570 patients)
LIORESAL (568 patients)
WARFARIN SODIUM (559 patients)
METFORMIN (535 patients)
LOVAZA (531 patients)
ACETYLSALICYLIC ACID SRT (528 patients)
PROZAC (526 patients)
INCIVEK (522 patients)
PERCOCET (520 patients)
ATIVAN (519 patients)
BYETTA (517 patients)
COREG (514 patients)
EPOGEN (510 patients)
LEVAQUIN (510 patients)
EFFEXOR (509 patients)
ASCORBIC ACID (509 patients)
ALEVE (507 patients)
MULTI-VITAMINS (506 patients)
DIGOXIN (501 patients)
ZANTAC (500 patients)
KLONOPIN (499 patients)
SANDOSTATIN LAR (497 patients)
LANSOPRAZOLE (494 patients)
AMOXICILLIN (490 patients)
EXJADE (485 patients)
DURAGESIC-100 (482 patients)
VITAMIN B-12 (480 patients)
RAMIPRIL (476 patients)
WELLBUTRIN (463 patients)
TEGRETOL (463 patients)
COZAAR (457 patients)
ALEVE (CAPLET) (441 patients)
COPEGUS (438 patients)
PRADAXA (435 patients)
BENICAR (434 patients)
SPIRONOLACTONE (432 patients)
TASIGNA (430 patients)
MULTIHANCE (422 patients)
ALPRAZOLAM (415 patients)
RENAGEL (412 patients)
OPTIMARK (409 patients)
INSULIN (408 patients)
ACCUTANE (405 patients)
PRAVASTATIN (397 patients)
GLIPIZIDE (396 patients)
LEVOXYL (395 patients)
ZOFRAN (392 patients)
GLUCOPHAGE (389 patients)
RANITIDINE (387 patients)
MORPHINE (386 patients)
JANUVIA (385 patients)
PEG-INTRON (384 patients)
CELEXA (383 patients)
FLOMAX (380 patients)
TRAZODONE HCL (379 patients)
TRICOR (378 patients)
DECADRON (370 patients)
AREDIA (368 patients)
DIAZEPAM (367 patients)
BEXTRA (365 patients)
VITAMIN E (365 patients)
VYTORIN (364 patients)
HUMALOG (363 patients)
VANCOMYCIN (362 patients)
DEXAMETHASONE (362 patients)
TYLENOL (CAPLET) (360 patients)
FLONASE (359 patients)
CARVEDILOL (357 patients)
CIPROFLOXACIN (357 patients)
ACTOS (355 patients)
ULTRAVIST 300 (354 patients)
CALCIUM CARBONATE (353 patients)
ARANESP (349 patients)
VALIUM (343 patients)
OXYCODONE HCL (343 patients)
CLARITIN (341 patients)
PROHANCE (340 patients)
TYLENOL (336 patients)
ATORVASTATIN CALCIUM (335 patients)
VOLTAREN (333 patients)
ATARAX (333 patients)
CARBOPLATIN (333 patients)
CLONIDINE (329 patients)
ALTACE (329 patients)
SYMBICORT (327 patients)
PAROXETINE HCL (325 patients)
LAMISIL (325 patients)
AMLODIPINE BESYLATE (322 patients)
ENALAPRIL MALEATE (321 patients)
PANTOPRAZOLE (319 patients)
VITAMINS (314 patients)
NITROGLYCERIN (313 patients)
METOPROLOL SUCCINATE (312 patients)
NAPROXEN (308 patients)
SOLU-MEDROL (305 patients)
ACTONEL (305 patients)
AMITRIPTYLINE HCL (303 patients)
FLUOROURACIL (302 patients)
PLAQUENIL (301 patients)
M.V.I. (299 patients)
ALENDRONATE SODIUM (298 patients)
LORTAB (297 patients)
GLYBURIDE (295 patients)
REBETOL (291 patients)
LOVASTATIN (287 patients)
BACTRIM (287 patients)
ERBITUX (286 patients)
IRON (286 patients)
ALDACTONE (285 patients)
FENTANYL (284 patients)
PROLIA (279 patients)
WELLBUTRIN XL (278 patients)
PROCRIT (277 patients)
ARAVA (277 patients)
POTASSIUM (275 patients)
FLUCONAZOLE (275 patients)
NOVOLOG (275 patients)
MIRENA (273 patients)
LOPRESSOR (266 patients)
ACYCLOVIR (266 patients)
PROVIGIL (265 patients)
NASONEX (264 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PRURITUS and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.